Chemically-Induced Disorders - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

RGD DISEASE ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:	Chemically-Induced Disorders	go back to main search page
Accession:	DOID:9008261	browse the term
Definition:	Disorders caused by the intentional or unintentional ingestion or exposure to chemical substances such as PHARMACEUTICAL PREPARATIONS; NOXAE; and PESTICIDES.
Synonyms:	exact_synonym:	Chemically-Induced Disorder
	narrow_synonym:	trichloroethylene-induced hypersensitivity
	primary_id:	MESH:D064419; RDO:0015820
	xref:	EFO:0007685
	subset:	RGD_JBrowse_slim

show annotations for term's descendants Sort by:
Rat (1431) Mouse (1366) Human (4452) Chinchilla (1135) Bonobo (1218) Dog (1303) Squirrel (1150) Pig (1281) Green Monkey (1205) Naked Mole-rat (1130) All
Genes (1340) QTL (66) Strains (25)

Chemically-Induced Disorders

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

apolipoprotein A4

CTD Direct Evidence: marker/mechanism

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

complement C3

CTD Direct Evidence: marker/mechanism

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement factor B

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

dipeptidase 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257

G

haptoglobin

CTD Direct Evidence: marker/mechanism

NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523

G

interleukin 10

CTD Direct Evidence: marker/mechanism

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

CTD Direct Evidence: marker/mechanism

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

CTD Direct Evidence: marker/mechanism

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lactotransferrin

CTD Direct Evidence: marker/mechanism

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Acute Alcohol Sensitivity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 2 family member

ClinVar Annotator: match by term: ALDH2-related condition | ClinVar Annotator: match by term: Alcohol sensitivity, acute | ClinVar Annotator: match by term: Susceptibility to hangover

PMID:2987944 PMID:4065146 PMID:6650498 PMID:7180842 PMID:7593603 More...

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

alcohol dependence

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenylate cyclase activating polypeptide 1

susceptibility

DNA:SNP:: (rs2856966) (human)

RGD

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

associated with other drug dependencies; DNA:SNPs:CDS: (rs904096)
ClinVar Annotator: match by term: Alcohol dependence

OMIM
ClinVar
RGD

PMID:3397059 PMID:3758060 PMID:10090900 PMID:15863807 PMID:17718394 More...

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

RGD

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

adrenoceptor alpha 2A

susceptibility

DNA:SNP:promoter: C-1291G (rs1800544) (human)
associated with stress-related disorder; mRNA:decreased expression:hypothalamus (rat)

RGD

PMID:21070505 PMID:26121187

RGD:401976462, RGD:401976544

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

argonaute RISC component 1

susceptibility

DNA:SNP:intron:A>G(rs595961)(human)

RGD

NCBI chr 5:138,722,111...138,757,118
Ensembl chr 5:138,722,111...138,773,546

G

argonaute RISC catalytic component 2

susceptibility

DNA:SNP:promoter:A>C(rs4961280)(human)

RGD

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

aryl hydrocarbon receptor

mRNA:decreased expression:duodenum:

RGD

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldehyde dehydrogenase 2 family member

ClinVar Annotator: match by term: Alcohol dependence
DNA:SNP: :1510G>A (human)

PMID:2987944 PMID:4065146 PMID:6650498 PMID:7180842 PMID:7593603 More...

RGD:401827938, RGD:401827936

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

angiopoietin 1

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs10090742)

RGD

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

ankyrin repeat and kinase domain containing 1

susceptibility

DNA:polymorphism:exon:
DNA:SNP,haplotype:exon:rs1800497(human)

RGD

PMID:28574012 PMID:23443985

RGD:401959222, RGD:401959307

NCBI chr 8:49,779,862...49,788,024
Ensembl chr 8:49,779,862...49,788,024

G

androgen receptor

severity

DNA:repeats:N-terminal
DNA:repeat, haplotype:exon

RGD

PMID:19231085 PMID:24271034

RGD:407424612, RGD:407550222

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

arrestin, beta 2

mRNA:decreased expression:nucleus accumbens

RGD

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

arginine vasopressin

protein:decreased expression:cerebrospinal fluid
protein:decreased expression:blood plasma
mRNA:increased expression:paraventricular nucleus of hypothalamus

RGD

PMID:7106059 PMID:15608610 PMID:9622448

RGD:408426006, RGD:596933105, RGD:529435544

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

arginine vasopressin receptor 1B

RGD

NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792

G

brain-derived neurotrophic factor

treatment
sexual_dimorphism

protein:altered expression:hippocampus

RGD

PMID:34453945 PMID:37303582 PMID:32579730

RGD:401959604, RGD:596936394, RGD:401959610

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

basic helix-loop-helix ARNT like 1

susceptibility

DNA:SNP::(rs6486120) (human)

RGD

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

basic helix-loop-helix ARNT like 2

susceptibility

DNA:SNPs, haplotype:: (rs7958822,rs4964057) (human)

RGD

NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949

G

bromodomain PHD finger transcription factor

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs11870068)

RGD

NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769

G

calcium voltage-gated channel subunit alpha1 C

mRNA, protein:increased expression:amygdala, hippocampus (rat)
protein:increased expression:inferior colliculus (human)

RGD

PMID:27905406 PMID:25556199

RGD:152985537, RGD:152985539

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

cholecystokinin

susceptibility

DNA:SNP:promoter: -45C>T (human)

RGD

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

cyclin-dependent kinase 20

susceptibility

DNA:SNP:: (rs560019) (human)

RGD

NCBI chr17:701,122...707,869
Ensembl chr17:701,124...707,826

G

choline O-acetyltransferase

protein:decreased expression:hippocampus,septum,striatum

RGD

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cholinergic receptor nicotinic alpha 3 subunit

susceptibility

DNA:missense:exons:p.R37H,p.E363D(human)

RGD

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic beta 3 subunit

susceptibility

DNA:missense:exons:multiple(human)

RGD

NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360

G

clock circadian regulator

exacerbates

RGD

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

catechol-O-methyltransferase

susceptibility
sexual_dimorphism
onset
disease_progression

associated with Alzheimer's disease; DNA:SNP:cd: P.V158M G>A (rs4680) (human)
DNA:SNPs,haplotypes:: (rs165774,rs4680) (human)
DNA:SNPs,haplotype:exon 4: p.V158M (rs4680) (human)
DNA:SNP:cd: p.V158M (rs4680) (human)
DNA:SNP:cd: p.V158M (human)
associated with major depressive disorder; DNA:SNP:cd: p.V158M (human)
DNA:polymorphism:exon 4: p.V158M (rs4680)(human)
associated with schizophrenia; DNA:promoter:Hypermethylation
associated with Trauma and Stressor Related Disorders ; DNA:polymorphism:exon: p.V158M (human)

RGD

PMID:25491588 PMID:22208661 PMID:16499480 PMID:24390676 PMID:16648777 More...

RGD:11073926, RGD:401959747, RGD:401959300, RGD:401940156, RGD:401940155, RGD:401940149, RGD:401940148, RGD:401940146, RGD:401940133, RGD:401940131, RGD:401940120, RGD:401940118

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carboxypeptidase E

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs10517844)
DNA:SNP:CDS: (rs13706874) (human)

RGD

PMID:27151647 PMID:20201924

RGD:405650603, RGD:405650609

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

cAMP responsive element binding protein 1

treatment

DNA:SNP:exon:rs35349697
protein:increased phosphorylation:prefrontal cortex (rat)
mRNA,protein:decreased expression:hippocampus

RGD

PMID:24704376 PMID:19324071 PMID:21951632 PMID:32579730 PMID:34453945 More...

RGD:401938627, RGD:401901600, RGD:401959743, RGD:401959610, RGD:401959604, RGD:401959603

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 2, subfamily d, polypeptide 4

protein:increased expression:brain

RGD

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

RGD

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

RGD

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

RGD

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

diazepam binding inhibitor

susceptibility
no_association

DNA:SNP:: +529A>T (rs8192503) (human)
DNA:SNP:: +529A>T (human)
DNA:SNP:: (rs2276596) (human)

RGD

PMID:18240651 PMID:21226341 PMID:24818357

RGD:408346758, RGD:408361841, RGD:408346759

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

DGCR8 microprocessor complex subunit

susceptibility

DNA:SNP:3��-UTR:G>T(rs1640299)(human)

RGD

NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242

G

dopamine receptor D1

RGD

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

onset
susceptibility

DNA:insertion, deletion:promoter:
DNA:SNP: :rs1800498(human)

RGD

PMID:23238469 PMID:36825486

RGD:401959213, RGD:401959301

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D4

no_association

DNA:repeats:exon:

RGD

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

FKBP prolyl isomerase 5

susceptibility

associated with stress-related disorder;DNA:SNP:: (rs1360780) (human)
associated with stress-related disorder;mRNA:affects expression:ventral tegmental area,cingulate cortex, nucleus accumbens( rat)
DNA:SNPs:intron,3'utr: (rs1360780, rs3800373)

RGD

PMID:27527158 PMID:27709495 PMID:27709495 PMID:27527158

RGD:401976484, RGD:401976487, RGD:401976487, RGD:401976484

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

formin 1

associated with other drug dependencies; DNA:SNPs:CDS: (rs3910705)

RGD

NCBI chr 3:100,101,103...100,485,652
Ensembl chr 3:100,134,549...100,479,220

G

Fos proto-oncogene, AP-1 transcription factor subunit

treatment

protein:increased expression:granular insular cortex, paraventricular nucleus of thalamus, prefrontal cortex

RGD

PMID:29926762 PMID:17723286 PMID:14574439 PMID:17360123

RGD:405100722, RGD:405295497, RGD:405101697, RGD:405100958

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

treatment

protein:increased expression:nucleus accumbens (rat)
associated with Sleep Deprivation;protein:increased expression:brain

RGD

PMID:20626732 PMID:19324071 PMID:33662520

RGD:401851075, RGD:401901600, RGD:401900733

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

FYN proto-oncogene, Src family tyrosine kinase

susceptibility
severity

DNA:SNP:5'utr: -93A>G (rs45490695) (human)
DNA:SNP:5'utr: T137346C (human)

RGD

PMID:18849153 PMID:14675807

RGD:408345238, RGD:408345249

NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911

G

gamma-aminobutyric acid type B receptor subunit 1

susceptibility
treatment

DNA:SNP, haplotype:intron: C>G (rs29220) (human)
DNA:SNP:Exon 11: T1974C (Human)
mRNA:decreased expression:hippocampus (rat)
DNA:SNP:intron: (rs29220) (human)
DNA:SNP:intron: (rs29253) (human)

RGD

PMID:26727527 PMID:36095322 PMID:36095322 PMID:10412185 PMID:22253714 More...

RGD:11552767, RGD:401976442, RGD:401976442, RGD:401959601, RGD:401900163, RGD:401940102, RGD:401940100

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

gamma-aminobutyric acid type B receptor subunit 2

mRNA:decreased expression:hippocampus (rat)

RGD

NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104

G

gamma-aminobutyric acid type A receptor subunit alpha 2

susceptibility

ClinVar Annotator: match by term: Alcohol dependence

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit beta 3

susceptibility

DNA:SNPs: :

RGD

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961

G

gamma-aminobutyric acid type A receptor subunit gamma 2

DNA:SNPs, haplotype:introns:IVS9+99C>A, IVS10+3145A>G (rs211014, rs211013) (human)
mRNA:decreased expression:hippocampus (human)
mRNA:increased expression:hippocampus (rat)

RGD

PMID:15630072 PMID:22253714 PMID:22253714

RGD:402463959, RGD:401900163, RGD:401900163

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glutamate decarboxylase 1

susceptibility
onset

DNA:SNPs, haplotype:5'UTR,IVS:Rs3749034,Rs2270335,Rs10439259(human)
DNA:SNPs: haplotype:multiple:rs1978340(human)

RGD

PMID:17067345 PMID:19111404

RGD:401900127, RGD:401900129

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

susceptibility

DNA:SNP::-243A>G (rs2236418)

RGD

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

glial cell derived neurotrophic factor

treatment

protein:decreased expression:serum

RGD

PMID:15659598 PMID:19232578 PMID:20553781 PMID:24801661

RGD:405820207, RGD:405850246, RGD:405849399, RGD:405849388

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

gem (nuclear organelle) associated protein 4

susceptibility

DNA:SNP:Promoter:C>T(rs910924)(human)

RGD

NCBI chr10:61,062,420...61,073,529
Ensembl chr10:61,066,425...61,073,431
Ensembl chr10:61,066,425...61,073,431

G

gamma-glutamyltransferase 1

protein:increased activity:plasma,liver,intestine:

RGD

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamate ionotropic receptor AMPA type subunit 1

ameliorates

RGD

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor NMDA type subunit 2A

susceptibility
ameliorates

DNA:repeats:promoter:(GT)n
DNA:mutation:cds:A825W(mouse)

RGD

PMID:21507155 PMID:33052417 PMID:29953905

RGD:401938633, RGD:401938638, RGD:401938635

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate metabotropic receptor 8

susceptibility

DNA:SNPs:intron 1: (rs886003, rs17862325) (human)

RGD

NCBI chr 4:55,805,762...56,731,690
Ensembl chr 4:55,805,955...56,730,831

G

glutathione S-transferase theta 1

RGD

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

5-hydroxytryptamine receptor 1A

mRNA:increased expression:Brodmann (1909) area 9
associated with nicotine dependence;DNA:SNPs:enhancer:multiple
DNA:SNP: :140G>C

RGD

PMID:22176604 PMID:23216389 PMID:19060480

RGD:401900608, RGD:405849412, RGD:401900293

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

susceptibility
onset
sexual_dimorphism
no_association

DNA:SNP:5'UTR:-161A>T (human)
DNA:SNP: :861G>C (human)
DNA:SNP: :861G>C(human)
DNA:SNP,haplotype:promoter:161A>T (human)
DNA:SNP:promoter:rs11568817 (human)

RGD

PMID:12022963 PMID:21906503 PMID:11104852 PMID:11827742 PMID:21172311 More...

RGD:405650693, RGD:405847406, RGD:405847401, RGD:405818273, RGD:405650698, RGD:405650694

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 2A

disease_progression
treatment
no_association

DNA:SNP: :102T>C (rs6313)
protein:decreased expression:agranular insular cortex, cingulate cortex, frontal cortex
DNA:SNP:promoter:-1438G>A (rs6311)

RGD

PMID:23321485 PMID:8822536 PMID:15080502 PMID:19328219 PMID:19060480 More...

RGD:401900291, RGD:401900739, RGD:401900737, RGD:401900304, RGD:401900293, RGD:401900297

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 3A

exacerbates
treatment
susceptibility

mRNA:increased expression:peripheral blood mononuclear cell (human)
DNA:SNPs:enhancer, exon: (rs1150226, rs1176713) (human)
DNA:SNPs, haplotype:multiple (human)
mRNA:increased expression:prefrontal cortex (rat)
DNA:SNP:exon 1: (rs33940208) (human)

RGD

PMID:27144979 PMID:23897038 PMID:24590108 PMID:25722691 PMID:23757001

RGD:404976874, RGD:405096433, RGD:404976878, RGD:404976876, RGD:404976875

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

interleukin 1 receptor antagonist

protein:increased expression:blood

RGD

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

potassium voltage-gated channel subfamily B member 2

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs2251898)

RGD

NCBI chr 5:3,567,012...4,028,564
Ensembl chr 5:3,569,685...4,028,599

G

leptin

severity

DNA:hypermethylation:promoter
DNA:hypomethylation:promoter
protein:decreased expression:serum

RGD

PMID:29912265 PMID:30650427 PMID:19884906 PMID:29912265

RGD:21201248, RGD:407572512, RGD:407424613, RGD:21201248

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

mitogen activated protein kinase 1

treatment

RGD

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

treatment

RGD

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

melanocortin 4 receptor

treatment

RGD

NCBI chr18:60,419,832...60,421,719
Ensembl chr18:60,419,832...60,421,719

G

neural cell adhesion molecule 1

susceptibility

DNA:SNPs:exon:

RGD

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

nerve growth factor

protein:increased expression:serum
protein:decreased expression:sciatic nerve
protein:decreased expression:plasma

RGD

PMID:17434673 PMID:8733743 PMID:16737466

RGD:401965399, RGD:401976493, RGD:401965409

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

protein:altered expression:brain,neuron

RGD

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

sodium/potassium transporting ATPase interacting 2

susceptibility

DNA:SNP: :rs637547 (human)

RGD

NCBI chr 1:24,668,627...25,877,051
Ensembl chr 1:24,669,462...25,877,064

G

neuropeptide Y

susceptibility

DNA:SNP:cd: p.L7P (rs16139) (human)

RGD

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 3, group C, member 1

treatment

RGD

PMID:25886852 PMID:26121746

RGD:408345235, RGD:408345252

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 3, group C, member 2

mRNA:altered expression:central amygdaloid nucleus (rat)

RGD

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

nurim

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs2269705)

RGD

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

neurexin 3

susceptibility

DNA:SNP,haplotype:Chr14:rs8019381, rs760288|rs8019381|2rs2293847 (human)

RGD

NCBI chr 6:107,641,760...109,272,849
Ensembl chr 6:107,641,780...109,272,044

G

neurotrophic receptor tyrosine kinase 2

onset

DNA:SNPs: :rs993315, rs10780691
DNA:SNP: :rs1439047

RGD

PMID:17200667 PMID:28512340

RGD:408395149, RGD:596933091

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

neurotensin receptor 1

susceptibility

DNA:SNPs,haplotype::rs6011914,rs2427422(human)

RGD

NCBI chr 3:167,606,215...167,656,371
Ensembl chr 3:167,606,215...167,656,377

G

nucleobindin 2

mRNA,protein:decreased expression:hippocampus

RGD

NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353

G

opioid receptor, delta 1

DNA:SNP,haplotype:intron 1 (rs2298896|rs421300), multiple GCAAT (human)

RGD

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

no_association

DNA:SNPs:intron:multiple
DNA:SNP,haplotype:multiple (multiple GGCTTCT) (human)
mRNA:increased expression:orbitofrontal cortex
DNA:SNP: :rs6473797 (human)

RGD

PMID:16924269 PMID:17622222 PMID:21955155 PMID:24035285

RGD:401850571, RGD:401976552, RGD:401850584, RGD:401850579

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

no_association
treatment
sexual_dimorphism

DNA:missense mutation:exon:p.N40D (118A>G) (rs 1799971) (human)
DNA:SNP: :rs1799971 (human)

RGD

PMID:16679777 PMID:24035285 PMID:30748046 PMID:11424981 PMID:35992511 More...

RGD:401827936, RGD:401850579, RGD:401831038, RGD:401827953, RGD:401827952, RGD:401827944, RGD:11097488, RGD:401827938, RGD:401827938

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

phosphodiesterase 4B

susceptibility

DNA:SNP:: (rs1937443) (human)

RGD

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

prodynorphin

no_association
disease_progression

DNA:SNP, hypermethylation:promoter:rs2235751 (human)
mRNA, protein:increased expression:dorsolateral prefrontal cortex, orbitofrontal cortex
DNA:SNP: :rs1997794 (human)
DNA:SNP, hypermethylation:dorsolateral prefrontal cortex:rs2281285 (human)
DNA:SNP: :rs2281285 (human)
DNA:SNPs: :multiple
DNA:SNPs, haplotypes:multiple

RGD

PMID:28336495 PMID:21955155 PMID:24035285 PMID:21521424 PMID:26502829 More...

RGD:401850551, RGD:401850584, RGD:401850579, RGD:401850575, RGD:11535796, RGD:401850571, RGD:401850565, RGD:401850560

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

period circadian regulator 2

DNA, mRNA:hypermethylation, decreased expression:blood
DNA:hypermethylation:blood, promoter

RGD

PMID:30597578 PMID:31329297

RGD:405878075, RGD:405878078

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

PBX/knotted 1 homeobox 2

associated with other drug dependencies; DNA:SNPs:CDS:intron (rs750338)

RGD

NCBI chr 8:36,600,633...36,863,131
Ensembl chr 8:36,600,636...36,790,940

G

proopiomelanocortin

no_association

DNA:SNP: :rs934778 (human)
DNA:hypermethylation:promoter:blood
mRNA:decreased expression:hypothalamus
mRNA:increased expression:pituitary gland
mRNA:increased expression:blood, lymphocyte
DNA:hypermethylation:blood, promoter
DNA, mRNA:hypermethylation, decreased expression:blood
mRNA:increased expression:blood, lymphocytes

RGD

PMID:24035285 PMID:24635847 PMID:20191296 PMID:11981131 PMID:7662043 More...

RGD:401850579, RGD:407572518, RGD:407431644, RGD:407424597, RGD:406179436, RGD:405878079, RGD:405878078, RGD:405878075, RGD:405878074

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

prolactin

treatment

RGD

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

regulator of G-protein signaling 6

associated with other drug dependencies; DNA:SNPs:CDS: (rs11621871)

RGD

NCBI chr 6:102,264,451...102,796,311
Ensembl chr 6:102,264,447...102,824,753

G

solute carrier family 29 member 1

OMIM:103780

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 6 member 1

susceptibility

DNA:insertion:promoter:: (human)

RGD

NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293

G

solute carrier family 6 member 2

susceptibility

DNA:SNPs,haplotypes:intron: (rs36020,rs36029) (human)

RGD

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 4

disease_progression

DNA:VNTR

RGD

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

taste receptor, type 2, member 118

NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:52,449,208...52,450,107

G

T-box transcription factor 19

susceptibility

DNA:SNP:: (rs1003502) (human)

RGD

NCBI chr13:77,450,848...77,484,475
Ensembl chr13:77,450,849...77,504,163

G

tetratricopeptide repeat domain 12

susceptibility

DNA:SNPs:introns,exon:

RGD

NCBI chr 8:49,799,916...49,847,940
Ensembl chr 8:49,799,920...49,847,087

Alcohol Myopathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

RGD

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

alcohol use disorder

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase short chain

susceptibility

DNA:SNP:: (rs1799958) (human)

RGD

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

CTD Direct Evidence: marker/mechanism

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 5 (class III), chi polypeptide

RGD

NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591

G

aldehyde dehydrogenase 2 family member

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16404797 PMID:17590986 PMID:10780266

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

ankyrin repeat and kinase domain containing 1

severity

DNA:polymorphism: :rs1800497(human)
DNA:SNP,haplotype: :rs11604671, rs4938015 (human)

RGD

PMID:32889058 PMID:21936764

RGD:401940151, RGD:401959296

NCBI chr 8:49,779,862...49,788,024
Ensembl chr 8:49,779,862...49,788,024

G

APC regulator of WNT signaling pathway 2

DNA, mRNA, protein:hypermethylation, decreased expression:brain

RGD

NCBI chr 7:9,392,336...9,414,364
Ensembl chr 7:9,392,336...9,414,310

G

activity-regulated cytoskeleton-associated protein

associated with Prenatal Exposure Delayed Effects and anxiety disorder:DNA:Hypermthylation:promoter

RGD

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

arginine vasopressin

mRNA:altered expression:central amygdaloid nucleus, medial amygdaloid nucleus, medial zone of hypothalamus
protein:decreased expression:suprachiasmatic nucleus

RGD

PMID:21575018 PMID:11709626

RGD:408364978, RGD:596933084

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

brain-derived neurotrophic factor

treatment

protein:decreased expression:plasma
mRNA, protein:altered expression:brain
protein:decreased expression:cerebellum, hippocampus
mRNA,protein:decreased expression:hippocampus, plasma (rat)
protein:decreased expression:plasma (human)

RGD

PMID:32135570 PMID:32330588 PMID:33919862 PMID:19100286 PMID:15307153 More...

RGD:35673317, RGD:596936412, RGD:596933362, RGD:401976492, RGD:401965482, RGD:401938665, RGD:401938665

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calbindin 1

mRNA:decreased expression:hippocampus (rat)

RGD

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

mRNA:increased expression:prefrontal cortex

RGD

NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600

G

calcium/calmodulin-dependent protein kinase IV

protein:decreased expression:brain, cingulate gyrus

RGD

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calpastatin

protein:increased expression:gastrocnemius (rat)

RGD

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

catalase

treatment

associated with diabetes; protein:decreased activity;testis, epididymis (rat)
associated with cardiomyopathy
associated with cognitive disorder; protein:altered activity:hippocampus (rat)
associated with diabetes;protein:decreased activity:liver, kidney (rat)

RGD

PMID:22596042 PMID:25541261 PMID:7195942 PMID:27367870 PMID:21713042

RGD:405255659, RGD:405255664, RGD:405255663, RGD:405255662, RGD:405255660

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin A receptor

CTD Direct Evidence: marker/mechanism

NCBI chr14:57,292,397...57,300,747
Ensembl chr14:57,292,397...57,300,747

G

cyclin-dependent kinase 20

CTD Direct Evidence: marker/mechanism

NCBI chr17:701,122...707,869
Ensembl chr17:701,124...707,826

G

cholinergic receptor nicotinic alpha 3 subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 5 subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146

G

cholinergic receptor nicotinic alpha 6 subunit

severity

DNA:haplotypes: :

RGD

NCBI chr16:64,697,741...64,704,441
Ensembl chr16:64,697,741...64,704,441

G

clock circadian regulator

susceptibility

DNA:SNP:: (rs2412648) (human)

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

cannabinoid receptor 1

sexual_dimorphism

associated with chronic stress in female rats

RGD

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

catechol-O-methyltransferase

disease_progression

CTD Direct Evidence: marker/mechanism
DNA:polymorphism: :rs4680(human)
DNA:polymorphism::

CTD
RGD

PMID:10395222 PMID:32889058 PMID:10395222

RGD:401940151, RGD:401940114

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cAMP responsive element binding protein 1

sexual_dimorphism

mRNA, protein:decreased expression:amygdala
protein:increased phosphorylation:liver
protein:altered expression, altered phosphorylation:liver, nucleus

RGD

PMID:29991681 PMID:31262967 PMID:22269225

RGD:401938626, RGD:401959334, RGD:401959317

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

mRNA, protein:decreased expression:amygdala

RGD

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

corticotropin releasing hormone

mRNA:increased expression:central amygdaloid nucleus (rat)

RGD

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

corticotropin releasing hormone receptor 1

RGD

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism
protein:increased expression:plasma, extracellular exosome

CTD
RGD

PMID:20843640 PMID:23819932 PMID:29404485 PMID:29404485

RGD:14700915, RGD:14700911, RGD:14700911

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

dopamine beta-hydroxylase

no_association

DNA:polymorphism:5' utr:g.-1021C>T (human)
DNA:polymorphism:cds:g.444G>A (human)

RGD

PMID:16133787 PMID:16252068

RGD:1625572, RGD:1625571

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

diazepam binding inhibitor

mRNA,protein:increased expression:cerebral cortex (mouse)

RGD

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

doublecortin

mRNA:decreased expression:hippocampus (rat)

RGD

NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476

G

discs large MAGUK scaffold protein 4

associated with Prenatal Exposure Delayed Effects and anxiety disorder:mRNA,protein:decreased expression:brain (mouse)

RGD

NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153

G

dopamine receptor D2

GAD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D4

treatment
susceptibility

DNA:repeats:exon:
associated with peer pressure;DNA:repeats:exon:

RGD

PMID:25640830 PMID:26307243

RGD:11064848, RGD:401959598

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

E1A binding protein p300

mRNA, protein:decreased expression:amygdala

RGD

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

ERCC excision repair 1, endonuclease non-catalytic subunit

RGD

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

fibroblast growth factor 2

RGD

PMID:28821667 PMID:31375540

RGD:405855870, RGD:405855874

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fragile X messenger ribonucleoprotein 1

mRNA:increased expression:cerebellum

RGD

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

Fos proto-oncogene, AP-1 transcription factor subunit

treatment

protein:increased expression:brain
protein:increased expression:parvocellular oculomotor nucleus

RGD

PMID:14741756 PMID:29210146 PMID:11164784

RGD:405255650, RGD:405295495, RGD:405255652

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

treatment

protein:increased expression:dorsal striatum (mouse)
protein:increased expression:brain (mouse)

RGD

PMID:22792289 PMID:27380261 PMID:9835277

RGD:401851082, RGD:401901287, RGD:401901184

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

follicle stimulating hormone subunit beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gamma-aminobutyric acid type B receptor subunit 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

gamma-aminobutyric acid type B receptor subunit 2

susceptibility

DNA:SNP:intron: (rs2900512) (human)

RGD

NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104

G

gamma-aminobutyric acid type A receptor subunit alpha 2

susceptibility

DNA:SNPs:multiple:
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:22253714 PMID:15024690

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit beta 3

susceptibility

DNA:CA repeats: :(human)

RGD

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961

G

gamma-aminobutyric acid type A receptor subunit gamma 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

GATA binding protein 4

CTD Direct Evidence: marker/mechanism

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

glial cell derived neurotrophic factor

treatment

protein:increased expression:serum
associated with Tobacco Use Disorder;mRNA:decreased expression:ventral tegmental area
DNA:hypomethylation:nucleus accumbens

RGD

PMID:25623403 PMID:28559549 PMID:22238721 PMID:31710958

RGD:401965480, RGD:405850249, RGD:405849387, RGD:405820205

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

gamma-glutamyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

growth hormone secretagogue receptor

CTD Direct Evidence: therapeutic

NCBI chr 2:110,268,489...110,271,865
Ensembl chr 2:110,268,489...110,271,865

G

gephyrin

CTD Direct Evidence: marker/mechanism

NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612

G

glutamate ionotropic receptor AMPA type subunit 1

protein:increased phosphorylation:lumbar spinal cord (mouse)
protein:decreased expression:neocortex (rat)
protein:increased expression, increased phosphorylation:cingulate cortex (rat)
protein:increased expression:nucleus accumbens (mouse)
protein:increased expression:nucleus accumbens (rat)

RGD

PMID:28585190 PMID:12036520 PMID:34280506 PMID:21041654 PMID:21041654

RGD:405100727, RGD:405820203, RGD:405818275, RGD:405650686, RGD:405650686

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

protein:decreased expression:neocortex (rat)
protein:increased expression:ventral CA1 field of hippocampus (rat)

RGD

PMID:12036520 PMID:30481568

RGD:405820203, RGD:596933081

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor NMDA type subunit 1

RGD

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

RGD

PMID:14573320 PMID:16911840

RGD:1642372, RGD:1642200

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

histone deacetylase 2

RGD

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

5-hydroxytryptamine receptor 1A

treatment

RGD

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

sexual_dimorphism
onset
no_association

associated with attention deficit hyperactivity disorder;DNA:SNP: :rs11568817(human)
DNA:SNP: :rs13212041 (human)
DNA:SNPs: :multiples (human)

RGD

PMID:28923721 PMID:30774345 PMID:11496363

RGD:405650695, RGD:405847403, RGD:405818272

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 2A

treatment

CTD Direct Evidence: marker/mechanism
protein:increased expression:dorsal raphe, nucleus accumbens
mRNA, protein:decreased expression:cerebral cortex, liver

CTD
RGD

PMID:9631953 PMID:9347073 PMID:9347075 PMID:20501057

RGD:401900760, RGD:401900742, RGD:401900740, RGD:401900301

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

treatment

RGD

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 3A

DNA:hypermethylation, hypomethylation:promoter: (mouse)

RGD

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

5-hydroxytryptamine receptor 3B

susceptibility

DNA:SNP:cds:rs1176744(human)

RGD

NCBI chr 8:49,279,291...49,308,444
Ensembl chr 8:49,279,173...49,308,444

G

5-hydroxytryptamine receptor 7

DNA:SNP:intron: (rs7916403) (human)

RGD

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

insulin-like growth factor 2

protein:decreased expression:plasma (human)

RGD

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

interleukin 10

mRNA:increased expression:liver

RGD

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

potassium inwardly-rectifying channel, subfamily J, member 6

DNA:SNP:promoter:rs2836016 (human)

RGD

NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758

G

potassium calcium-activated channel subfamily N member 2

protein:decreased expression:ventral CA1 field of hippocampus (rat)

RGD

NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347

G

luteinizing hormone subunit beta

CTD Direct Evidence: marker/mechanism

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

monoamine oxidase A

susceptibility

RGD

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase 1

protein:increased expression:liver

RGD

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

protein:increased expression, increased phosphorylation:liver

RGD

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

protein:increased expression:liver

RGD

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

RGD

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

myoglobin

protein:decreased expression:serum

RGD

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

minichromosome maintenance complex component 5

RGD

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

microRNA 191

onset

RGD

NCBI chr 8:109,264,098...109,264,188

G

microRNA 195

onset

RGD

NCBI chr10:54,951,838...54,951,924
Ensembl chr10:54,951,838...54,951,924

G

microRNA 206

onset

RGD

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332

G

microRNA 30a

onset

RGD

NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670

G

marker of proliferation Ki-67

mRNA:decreased expression:hippocampus (rat)

RGD

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

RGD

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

RGD

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

neural cell adhesion molecule 1

sexual_dimorphism
treatment

mRNA:decreased expression:hippocampus (rat)
associated with chronic stress in female rats

RGD

PMID:30277635 PMID:27894930 PMID:16207289

RGD:401938665, RGD:401959751, RGD:401959613

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

nerve growth factor

protein:increased expression:serum
protein:decreased expression:cerebral cortex, hippocampus
protein:decreased expression:brain

RGD

PMID:25623403 PMID:19100286 PMID:15307153

RGD:401965480, RGD:401976492, RGD:401965482

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

neuropeptide Y

DNA:deletion:intron:g.4666_4674del (rat)
CTD Direct Evidence: marker/mechanism
DNA:missense mutation: :p.L7P (human)

CTD
RGD

PMID:17572454 PMID:15749341 PMID:12215082

RGD:1357412, RGD:10430830

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

neuropeptide Y receptor Y2

CTD Direct Evidence: marker/mechanism

NCBI chr 2:167,901,999...167,912,165
Ensembl chr 2:167,903,879...167,905,024

G

nuclear receptor subfamily 3, group C, member 1

treatment

protein:decreased expression, decreased DNA binding:brain
mRNA, protein:decreased expression:placenta

RGD

PMID:11961084 PMID:21143252 PMID:31756338 PMID:33920737

RGD:408345232, RGD:408345244, RGD:408345241, RGD:408345239

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 3, group C, member 2

treatment
sexual_dimorphism

RGD

PMID:29437012 PMID:30171933 PMID:33007359

RGD:401965466, RGD:401976281, RGD:401966865

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

neuregulin 1

sexual_dimorphism

in female, associated with stressful life event;DNA:SNP: :rs6994992(human)

RGD

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurotrophin 3

protein:decreased expression:plasma (human)
protein:increased expression:brain
mRNA,protein:decreased expression:hippocampus, plasma (rat)

RGD

PMID:30277635 PMID:15307153 PMID:30277635

RGD:401938665, RGD:401965482, RGD:401938665

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

neurotrophic receptor tyrosine kinase 2

treatment

associated with Prenatal Exposure Delayed Effects and anxiety disorder:protein:decreased acetylation:brain

RGD

PMID:30016666 PMID:33919862 PMID:32206827 PMID:8840027

RGD:401959614, RGD:596933362, RGD:596933095, RGD:401965407

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

opioid receptor, delta 1

associated with stress-related disorder; mRNA:decreased expression:dorsal striatum (rat)
DNA:SNPs, haplotype:intron 1:multiple (human)

RGD

PMID:28511993 PMID:24533225 PMID:7501658

RGD:401976432, RGD:402525443, RGD:401976439

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

severity
susceptibility
no_association

DNA:SNP, haplotype: :rs6473797 (human)
associated with stress-related disorder; mRNA:decreased expression:dorsal striatum (rat)
DNA:SNP: :rs6473797 (human)
DNA:SNP: :rs997917 (human)

RGD

PMID:31004399 PMID:28511993 PMID:37177778 PMID:37177778

RGD:401831037, RGD:401976432, RGD:401850581, RGD:401850581

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid related nociceptin receptor 1

RGD

NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920

G

opioid receptor, mu 1

treatment
no_association

CTD Direct Evidence: marker/mechanism
DNA:missense mutation:exon:p.N40D (118A>G) (rs 1799971) (human)
DNA:missense mutations, SNP:exon, intron:p.A6V, p.S147C, p.N40D (118A>G) (rs 1799971), IVS2+691G>C (human)
DNA:SNP: :rs510769

CTD
RGD

PMID:12815747 PMID:32772383 PMID:9399694 PMID:26042510

RGD:401827947, RGD:401827934, RGD:401827930

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

phosphodiesterase 4B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

prodynorphin

no_association
susceptibility

CTD Direct Evidence: marker/mechanism
mRNA, protein:decreased expression:hippocampus, granule cell
DNA:SNPs: :rs2281285, rs2225749, rs910080 (human)
DNA:SNP: :rs2281285 (human)
DNA, mRNA:SNP, decreased expression:promoter, dorsolateral prefrontal cortex:rs1997794 (human)
associated with cocaine dependence;DNA, mRNA:SNPs, haplotype:3' utr:rs910080, rs910079, rs2235749 (human)

CTD
RGD

PMID:17559549 PMID:18923396 PMID:1589146 PMID:37177778 PMID:36099111 More...

RGD:401851059, RGD:401850581, RGD:401850566, RGD:401850559, RGD:401850550

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

proenkephalin

mRNA:increased expression:frontal lobe:

RGD

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

period circadian regulator 1

mRNA:altered expression: arcuate nucleus of hypothalamus

RGD

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

mRNA:altered expression: arcuate nucleus of hypothalamus, suprachiasmatic nucleus

RGD

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

mRNA:altered expression:suprachiasmatic nucleus

RGD

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

proopiomelanocortin

sexual_dimorphism

protein:decreased expression:brain (rat)
mRNA:altered expression: arcuate nucleus of hypothalamus
associated with Prenatal Exposure Delayed Effects;mRNA:altered expression:adenohypophysis
protein:increased expression:plasma
mRNA, protein:increased expression:arcuate nucleus, hypothalamus, septum
DNA, mRNA:deletion, decreased expression:enhancer, hypothalamus
mRNA:increased expression: hypothalamus, pituitary gland, shell of nucleus accumbens

RGD

PMID:18162070 PMID:15009656 PMID:19912941 PMID:19912941 PMID:7925590 More...

RGD:401976284, RGD:407572515, RGD:407572513, RGD:407572513, RGD:407571692, RGD:407550221, RGD:405878072

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

ribosomal protein L18A

mRNA:decreased expression:parietal cortex

RGD

NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546
Ensembl chr 1:18,542,566...18,545,546

G

selectin L

protein:decreased expression:Tcell

RGD

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

sex hormone binding globulin

CTD Direct Evidence: marker/mechanism

NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057

G

solute carrier family 6 member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

susceptibility

protein:decreased activity: :
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:15520362 PMID:17000009 PMID:20838391

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

synuclein alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

superoxide dismutase 1

associated with diabetes; protein:decreased activity;testis, epididymis (rat)

RGD

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

SRY-box transcription factor 2

mRNA:decreased expression:hippocampus (rat)

RGD

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

Spi-1 proto-oncogene

treatment

protein:decreased expression:alveolar macrophage

RGD

PMID:16272341 PMID:21447000

RGD:9586723, RGD:9586725

NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393

G

sialophorin

associated with Prenatal Exposure Delayed Effects and anxiety disorder:DNA:Hypermthylation:promoter

RGD

NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628

G

ST6 beta-galactoside alpha-2,6-sialyltransferase 1

severity

mRNA,protein:decreased expression:liver:

RGD

NCBI chr11:77,526,837...77,653,474
Ensembl chr11:77,526,837...77,653,310

G

synaptophysin

sexual_dimorphism

associated with chronic stress in female rats

RGD

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

tachykinin receptor 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733

G

tachykinin receptor 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:223,266,536...223,363,791
Ensembl chr 2:223,266,536...223,363,791

G

taste receptor, type 2, member 118

CTD Direct Evidence: marker/mechanism

PMID:16385453 PMID:17250611

NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:52,449,208...52,450,107

G

taste receptor, type 2, member 138

CTD Direct Evidence: marker/mechanism

NCBI chr 4:69,428,344...69,429,339
Ensembl chr 4:69,428,344...69,429,339

G

T-box transcription factor 19

CTD Direct Evidence: marker/mechanism

NCBI chr13:77,450,848...77,484,475
Ensembl chr13:77,450,849...77,504,163

G

transferrin

CTD Direct Evidence: marker/mechanism

PMID:11000917 PMID:21792595

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

timeless circadian regulator

susceptibility

DNA:SNP:: (rs2291738) (human)

RGD

NCBI chr 7:654,804...678,769
Ensembl chr 7:654,822...678,738

G

tryptophan hydroxylase 1

RGD

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

G

vasoactive intestinal peptide

susceptibility

DNA:SNPs, haplotype:: (rs3823082,rs688136) (human)

NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216

Alcohol Withdrawal Delirium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholecystokinin

susceptibility

DNA:SNP:promoter: -45C>T (human)

RGD

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

cannabinoid receptor 1

RGD

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

nerve growth factor

protein:increased expression:serum

RGD

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

prostaglandin-endoperoxide synthase 2

RGD

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

solute carrier family 6 member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

Alcohol Withdrawal Seizures

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium voltage-gated channel subunit alpha1 D

susceptibility

mRNA, protein:increased expression:inferior colliculus (rat)

RGD

NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215

G

dopamine receptor D2

susceptibility

DNA:SNP:exon:A>G(human)

RGD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

prodynorphin

mRNA:increased expression:brain

RGD

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

solute carrier family 29 member 1

CTD Direct Evidence: marker/mechanism

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 6 member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

alcohol withdrawal syndrome

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arginine vasopressin

protein:decreased expression:suprachiasmatic nucleus
DNA:hypermethylation:promoter

RGD

PMID:11709626 PMID:24356727

RGD:596933084, RGD:596933307

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

brain-derived neurotrophic factor

severity

protein:increased expression:hippocampus, prefrontal cortex

RGD

PMID:20553781 PMID:26659122

RGD:405849399, RGD:596936245

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

basic helix-loop-helix ARNT like 1

severity

mRNA:decreased expression:peripheral blood mononuclear cells (human)

RGD

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

clock circadian regulator

severity

mRNA:decreased expression:peripheral blood mononuclear cells (human)

RGD

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

cryptochrome circadian regulator 1

severity

mRNA:decreased expression:peripheral blood mononuclear cells (human)

RGD

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

cryptochrome circadian regulator 2

mRNA:decreased expression:Peripheral blood mononuclear cell (human)

RGD

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

cytochrome P450, family 2, subfamily C, polypeptide 6

no_association
treatment

DNA:SNPs::CYP2C19*2 (681G>A,rs4244285), CYP2C19*3 (636G>A, rs4986893),CYP2C19*17 (-806C>T, rs12248560) (human)
DNA:SNP:promoter:CYP2C19*17 (-806C>T,rs12248560)(human)
DNA:SNP:cds:CYP2C19*2 (681G>A,rs4244285)(human)

RGD

PMID:27099220 PMID:30325732 PMID:31957548

RGD:401960863, RGD:401960882, RGD:401960880

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

diazepam binding inhibitor

mRNA,protein:increased expression:cerebral cortex (mouse)

RGD

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

dopamine receptor D4

severity

DNA:repeats:exon:

RGD

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

FKBP prolyl isomerase 5

severity

DNA:SNPs,haplotypes:multiple

RGD

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

Fos proto-oncogene, AP-1 transcription factor subunit

treatment

protein:altered expression:brain

RGD

PMID:26727528 PMID:31778691

RGD:405101372, RGD:405255665

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

disease_progression

protein:increased expression:primary motor cortex, secondary motor cortex, ventral tegmental area (mouse)

RGD

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

gamma-aminobutyric acid type A receptor subunit gamma 2

mRNA, protein:increased expression:hippocampus (rat)

RGD

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glial cell derived neurotrophic factor

mRNA, DNA:altered expression, hypomethylation:brain

RGD

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glutamate ionotropic receptor AMPA type subunit 1

protein:increased phosphorylation:lateral habenular nucleus (rat)

RGD

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

nerve growth factor

protein:increased expression:plasma

RGD

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

neuropeptide Y receptor Y1

mRNA:decreased expression:hippocampus, cerebral cortex (rat)

RGD

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

nuclear receptor subfamily 3, group C, member 1

protein:decreased phosphorylation:prefrontal cortex
protein:decreased expression:cingulate gyrus

RGD

PMID:25732140 PMID:18801418 PMID:11961084

RGD:408345231, RGD:408345247, RGD:408345232

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neurotrophic receptor tyrosine kinase 2

treatment

associated with Binge Drinking
protein:increased phopsphorylation, increased expression:hippocampus, prefrontal cortex

RGD

PMID:24076087 PMID:26659122 PMID:37366469

RGD:596933360, RGD:596936245, RGD:596933361

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

period circadian regulator 1

severity

mRNA:decreased expression:peripheral blood mononuclear cells (human)

RGD

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

severity

mRNA:decreased expression:Peripheral blood mononuclear cell (human)

RGD

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

proopiomelanocortin

mRNA:increased expression:hypothalamus
protein:decreased expression:plasma

RGD

PMID:11981131 PMID:11704624 PMID:9406908 PMID:31117084

RGD:407424597, RGD:407550224, RGD:407550223, RGD:407431638

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

prolactin

treatment

RGD

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

Alcohol-Induced Disorders, Nervous System

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

allograft inflammatory factor 1

protein:increased expression:cortex, hippocampus (rat)

RGD

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

cold inducible RNA binding protein

CTD Direct Evidence: marker/mechanism

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

alcohol-induced mental disorder

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 2 family member

CTD Direct Evidence: marker/mechanism

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

ankyrin repeat and kinase domain containing 1

DNA:SNP:exon:rs1800497(human)

RGD

NCBI chr 8:49,779,862...49,788,024
Ensembl chr 8:49,779,862...49,788,024

G

dopamine receptor D2

DNA:SNP:cds:957C>T(human)

RGD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

forkhead box O4

protein:increased phosphorylation:small intestine:

RGD

NCBI chr X:66,385,241...66,392,115
Ensembl chr X:66,385,558...66,392,115

G

glutathione-disulfide reductase

treatment

RGD

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

HECT domain E3 ubiquitin protein ligase 4

CTD Direct Evidence: marker/mechanism

NCBI chr12:35,182,165...35,330,935
Ensembl chr12:35,182,154...35,330,987

Alcohol-Induced Sudden Cardiac Failure

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

inorganic pyrophosphatase 2

ClinVar Annotator: match by term: PPA2-related condition | ClinVar Annotator: match by term: Sudden cardiac failure, alcohol-induced

PMID:24033266 PMID:25741868 PMID:27523597 PMID:27523598 PMID:28492532 More...

NCBI chr 2:221,800,791...221,878,079
Ensembl chr 2:221,800,842...221,878,081

Alcohol-Related Disorders

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain-derived neurotrophic factor

sexual_dimorphism

protein:altered expression:brain
protein:altered expression:frontal cortex,hippocampus,occipital cortex
protein:altered expression:cerebral cortex

RGD

PMID:10837897 PMID:18652597 PMID:14604765

RGD:401965408, RGD:401976540, RGD:401976539

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

CART prepropeptide

CTD Direct Evidence: marker/mechanism

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 8

treatment

RGD

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

Cd4 molecule

sexual_dimorphism

associated with Mycobacterium Infections;protein:decreased expression:spleen (rat)
protein:increases expression:spleen (rat)

RGD

PMID:9744851 PMID:8214423

RGD:407446372, RGD:407446376

NCBI chr 4:157,668,878...157,695,366
Ensembl chr 4:157,668,878...157,695,191

G

corticotropin releasing hormone

sexual_dimorphism

mRNA:increased expression:fetus, thymus

RGD

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

Fos proto-oncogene, AP-1 transcription factor subunit

protein:increased expression:liver

RGD

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

Jun proto-oncogene, AP-1 transcription factor subunit

protein:increased expression:liver

RGD

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

nerve growth factor

protein:altered expression:brain
protein:decreased expression:entorhinal cortex
protein:increased expression:frontal cortex,cerebellar vermis
protein:increased expression:cerebral cortex
protein:increased expression:thalamus

RGD

PMID:10837897 PMID:10440485 PMID:18652597 PMID:14604765 PMID:21277941

RGD:401965408, RGD:401976542, RGD:401976540, RGD:401976539, RGD:401976494

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

protein:decreased expression:brain
protein:altered expression:brain

RGD

PMID:15188276 PMID:15188277

RGD:401976554, RGD:401976555

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nuclear receptor subfamily 3, group C, member 1

RGD

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neurotrophin 3

protein:increased expression:hippocampus,cerebellar vermis

RGD

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

neurotrophic receptor tyrosine kinase 1

protein:altered expression:brain
protein:decreased expression:brain

RGD

PMID:15188276 PMID:15188277

RGD:401976554, RGD:401976555

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

neurotrophic receptor tyrosine kinase 2

protein:altered expression:brain

RGD

PMID:15188276 PMID:15188277

RGD:401976554, RGD:401976555

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

neurotrophic receptor tyrosine kinase 3

protein:altered expression:brain

RGD

PMID:15188276 PMID:15188277

RGD:401976554, RGD:401976555

NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286

G

opioid receptor, kappa 1

treatment

RGD

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

proopiomelanocortin

sexual_dimorphism

mRNA:decreased expression:fetus, thymus

RGD

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

alcoholic cardiomyopathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

GAD

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensinogen

CTD Direct Evidence: marker/mechanism

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

autophagy related 3

treatment

RGD

NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224

G

autophagy related 7

treatment

RGD

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

beclin 1

treatment

RGD

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

nitric oxide synthase 1

protein:decreased expression:skeletal muscle, membrane

RGD

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

peroxisome proliferator-activated receptor gamma

protein:increased expression:heart myocardium

RGD

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

retinoid X receptor alpha

RGD

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

solute carrier family 25 member 4

mRNA, protein:decreased expression:myocardium

RGD

NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733

alcoholic hepatitis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

treatment

RGD

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

angiotensinogen

mRNA:decreased expression:liver

RGD

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

protein:altered expression:hepatocyte

RGD

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

protein:increased expression:liver

RGD

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

severity

protein:increased expression, modification:urine

RGD

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

autophagy related 3

treatment

RGD

NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224

G

autophagy related 7

treatment

protein:increased expression:liver

RGD

PMID:31090940 PMID:36308627

RGD:407445926, RGD:407532639

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

beclin 1

protein:increased expression:liver

RGD

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

C-C motif chemokine ligand 2

severity

RNA:increased expression:liver:

RGD

PMID:24429361 PMID:21826694 PMID:10446112

RGD:14975280, RGD:14995491, RGD:14995467

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

severity

RGD

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12586603 PMID:31258651

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

collagen type I alpha 1 chain

RGD

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

carnitine palmitoyltransferase 1A

treatment

RGD

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cytochrome P450 family 7 subfamily A member 1

treatment

RGD

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

discoidin domain receptor tyrosine kinase 1

disease_progression
severity

mRNA:increased expression:liver (mouse)
mRNA:increased expression:liver (human)

RGD

PMID:33173221 PMID:33173221

RGD:151347691, RGD:151347691

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

Fas cell surface death receptor

treatment

RGD

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

fibroblast growth factor 19

treatment

RGD

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

intercellular adhesion molecule 1

severity

protein:increased expression:hepatocyte

RGD

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 13

mRNA:increased expression:liver

RGD

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

severity

associated alcoholic liver cirrhosis; protein:increased expression:plasma:

RGD

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

microRNA 155

ameliorates

RNA:increased expression:liver

RGD

PMID:32317960 PMID:31090940

RGD:151347420, RGD:407445926

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

mechanistic target of rapamycin kinase

protein:decreased expression:liver

RGD

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nuclear factor kappa B subunit 1

treatment

RGD

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

treatment

RGD

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

treatment

RGD

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

NAD(P)H quinone dehydrogenase 1

protein:altered expression:hepatocyte

RGD

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

treatment

RGD

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

treatment

RGD

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

peroxisome proliferator activated receptor alpha

treatment

RGD

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

selectin L

treatment

mRNA:increased expression:liver

RGD

PMID:10782906 PMID:9835285

RGD:597015742, RGD:597015743

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

solute carrier family 10 member 1

treatment

RGD

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

suppressor of cytokine signaling 1

mRNA:decreased expression:liver

RGD

NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383

G

sequestosome 1

treatment

protein:increased expression:liver

RGD

PMID:31090940 PMID:36308627

RGD:407445926, RGD:407532639

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

treatment

RGD

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroid sulfatase

CTD Direct Evidence: marker/mechanism

NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402

G

sulfotransferase family 1E member 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

tumor necrosis factor

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:12586603 PMID:27939985

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Alcoholic Intoxication

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activity-regulated cytoskeleton-associated protein

disease_progression

mRNA:altered expression:brain (mouse)

RGD

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

brain-derived neurotrophic factor

mRNA,protein:decreased expression:cerebellum

RGD

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

dopamine receptor D2

treatment

RGD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

Fos proto-oncogene, AP-1 transcription factor subunit

protein:altered expression:brain
mRNA:decreased expression:adrenal gland

RGD

PMID:26727528 PMID:12351928

RGD:405101372, RGD:405255666

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glial cell derived neurotrophic factor

mRNA:decreased expression:basal nucleus

RGD

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

interferon gamma

treatment

RGD

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

nerve growth factor

mRNA,protein:increased expression:cerebellum
protein:increased expression:plasma

RGD

PMID:19861148 PMID:18639986

RGD:401965398, RGD:401965411

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

neuropeptide S

RGD

NCBI chr 1:190,077,040...190,080,821
Ensembl chr 1:190,077,040...190,080,821

G

neuropeptide S receptor 1

mRNA:increased expression:brain

RGD

NCBI chr 8:22,606,946...22,831,558
Ensembl chr 8:22,606,946...22,831,558

G

nuclear receptor subfamily 3, group C, member 1

sexual_dimorphism

DNA:SNP: :rs244465

RGD

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neurotrophic receptor tyrosine kinase 1

mRNA,protein:increased expression:cerebellum

RGD

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

neurotrophic receptor tyrosine kinase 2

mRNA:increased expression:basal nucleus, cerebral cortex

RGD

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

period circadian regulator 2

CTD Direct Evidence: marker/mechanism

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

alcoholic liver cirrhosis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 2 family member

susceptibility

DNA:missense mutation:cds:p.E504K (human)
DNA:missense mutation:cds: (rs671) (human)
associated with alcohol dependence;DNA:missense mutation:exon 12:p.E487K (human)

RGD

PMID:29779728 PMID:23550892 PMID:11051375

RGD:14696777, RGD:15042864, RGD:15042858

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

BCL2, apoptosis regulator

CTD Direct Evidence: marker/mechanism

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

complement C3

RGD

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

catalase

CTD Direct Evidence: marker/mechanism

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

2',3'-cyclic nucleotide 3' phosphodiesterase

protein:decreased expression:brain

RGD

NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720

G

collagen type III alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

C-reactive protein

severity

RGD

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome P450, family 2, subfamily e, polypeptide 1

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20843640 PMID:29404441

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

discoidin domain receptor tyrosine kinase 1

severity

mRNA:increased expression:liver (human)

RGD

NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468

G

discoidin domain receptor tyrosine kinase 2

disease_progression
ameliorates

RGD

PMID:21199726 PMID:23409069

RGD:150429766, RGD:150517731

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

fatty acid binding protein 2

onset

DNA:polymorphism:CDS:amino acid A54T, homozygosity of the T allele associated with later onset

PMID:16289894 PMID:16289894

RGD:1578455, RGD:1578455

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

gamma-aminobutyric acid type A receptor subunit gamma 2

susceptibility

DNA:SNP:intron 8:84435G>A (human)

RGD

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

interleukin 18 binding protein

protein:increased expression:plasma:

RGD

NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963

G

interleukin 6

CTD Direct Evidence: marker/mechanism

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Janus kinase 2

mRNA, protein:increased expression, increased tyrosine phosphorylation:liver

RGD

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

leptin

DNA:hypomethylation:promoter (human)

RGD

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

membrane bound O-acyltransferase domain containing 7

CTD Direct Evidence: marker/mechanism

NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538

G

microRNA 122

miRNA:decreased expression:liver

RGD

NCBI chr18:58,758,703...58,758,787

G

microRNA 141

CTD Direct Evidence: marker/mechanism

NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332

G

microRNA 17

CTD Direct Evidence: marker/mechanism

NCBI chr15:92,180,629...92,180,712
Ensembl chr15:92,180,629...92,180,712

G

microRNA 193b

CTD Direct Evidence: marker/mechanism

NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824

G

microRNA 423

CTD Direct Evidence: marker/mechanism

NCBI chr10:61,914,142...61,914,220
Ensembl chr10:61,914,133...61,914,226

G

microRNA 484

CTD Direct Evidence: marker/mechanism

NCBI chr10:887,684...887,760
Ensembl chr10:887,684...887,760

G

microRNA 532

CTD Direct Evidence: marker/mechanism

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 93

CTD Direct Evidence: marker/mechanism

NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221

G

matrix metallopeptidase 13

RGD

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

CTD Direct Evidence: marker/mechanism

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myeloperoxidase

CTD Direct Evidence: marker/mechanism

PMID:19731237 PMID:23274713

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

methylenetetrahydrofolate reductase

susceptibility

DNA:SNP: :677C>T(human)

RGD

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

nuclear receptor subfamily 1, group D, member 1

RGD

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

plasminogen activator, urokinase

RGD

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

patatin-like phospholipase domain containing 3

CTD Direct Evidence: marker/mechanism

PMID:19946271 PMID:26482880

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

serpin family E member 1

susceptibility

DNA:polymorphism:promoter:

RGD

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

serpin family F member 1

protein:increased expression:serum (human)

RGD

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

G

SMAD family member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

superoxide dismutase 2

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:SNP: : 47T>C(human)

CTD
RGD

PMID:19731237 PMID:26873981

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

thyroglobulin

RGD

NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210

G

transforming growth factor, beta 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

CTD Direct Evidence: marker/mechanism

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

toll-like receptor 9

protein:increased expression:blood, neutrophil (human)

RGD

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

transmembrane 6 superfamily member 2

CTD Direct Evidence: marker/mechanism

NCBI chr16:19,344,218...19,351,431
Ensembl chr16:19,344,222...19,351,431

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

Alcoholic Liver Diseases

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

severity
treatment

protein:increased activity:serum (human)

RGD

PMID:3028446 PMID:28691216

RGD:19165343, RGD:40400719

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adiponectin receptor 2

treatment

RGD

NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355

G

aryl hydrocarbon receptor

exacerbates
ameliorates

RGD

PMID:34454169 PMID:36871955

RGD:405866377, RGD:405866378

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

treatment

RGD

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 2 family member

susceptibility
severity

DNA:missense mutation:cds, exon 12:p.E487K (human)
DNA:polymorphism:exon 12: (human)
DNA:deletion:cds: (mouse)

RGD

PMID:1916152 PMID:12198368 PMID:26173414 PMID:3189338

RGD:14696699, RGD:14981580, RGD:11076022, RGD:14696790

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

angiopoietin 2

severity

RGD

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804

G

autophagy related 7

protein:increased expression:liver

RGD

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

beclin 1

protein:increased expression:liver

RGD

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

betaine-homocysteine S-methyltransferase

protein:increased expression:cytosol

RGD

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

complement C6

resistance

RGD

NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275

G

carbonic anhydrase 3

protein:decreased expression:cytosol

RGD

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

catalase

treatment

RGD

PMID:8370342 PMID:28898587

RGD:405255646, RGD:405255658

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

treatment

RGD

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

CD27 molecule

RGD

NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592

G

CD59b molecule

protein:decreased expression:liver

RGD

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

claudin 1

treatment

RGD

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

carbamoyl-phosphate synthase 1

protein:increased expression:cytosol

RGD

NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033

G

cytotoxic T-lymphocyte-associated protein 4

susceptibility

DNA:SNP::-318 T>C(rs5742909)(human)

RGD

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

C-X-C motif chemokine ligand 1

mRNA:increased expression:liver

RGD

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 2

mRNA:increased expression:liver

RGD

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 6

mRNA:increased expression:liver

RGD

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

cytochrome P450, family 2, subfamily e, polypeptide 1

treatment

RGD

PMID:29401608 PMID:9927612 PMID:30192013 PMID:25592162 PMID:29902864

RGD:14700887, RGD:405650696, RGD:14700906, RGD:14700894, RGD:14700893

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

RGD

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

epidermal growth factor receptor

RGD

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

RGD

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

Fas cell surface death receptor

protein:increased expression:lymphocyte:

RGD

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

FKBP prolyl isomerase 5

ameliorates

mRNA,protein:incrased expression:liver (human)

RGD

PMID:33710653 PMID:33710653

RGD:401976495, RGD:401976495

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

glial cell derived neurotrophic factor

protein:increased expression:serum
mRNA,protein:increased expression:liver

RGD

PMID:35338490 PMID:35338490

RGD:405849393, RGD:405849393

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glutathione S-transferase mu 1

RGD

PMID:15932176 PMID:26937962

RGD:14700973, RGD:11060494

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase theta 1

RGD

PMID:15932176 PMID:26937962

RGD:14700973, RGD:11060494

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

homeostatic iron regulator

mRNA:increased expression:liver, Kupffer cell (rat)

RGD

NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502

G

hypoxia inducible factor 1 subunit alpha

mRNA:increased expression:liver (rat)

RGD

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

insulin-like growth factor 2

mRNA:increased expression:liver

RGD

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

interleukin 1 beta

protein:increased expression:serum (rat)

RGD

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

treatment

RGD

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Kelch-like ECH-associated protein 1

mRNA:decreased expression:liver (human)

RGD

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

lipoprotein lipase

treatment

RGD

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

macrophage migration inhibitory factor

protein:increased expression:liver

RGD

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
Ensembl chr 4:12,790,902...12,799,504

G

microRNA 122

miRNA:decreased expression:hepatocyte

RGD

NCBI chr18:58,758,703...58,758,787

G

microRNA 155

ameliorates

RNA:increased expression:liver

RGD

PMID:28492308 PMID:31090940 PMID:31090940

RGD:25314298, RGD:407445926, RGD:407445926

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

microRNA 223

severity

RGD

NCBI chr X:61,141,887...61,141,996
Ensembl chr X:61,141,887...61,141,996

G

matrix metallopeptidase 9

protein:increased expression:liver

RGD

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

protein:decreased expression:liver

RGD

PMID:31090940 PMID:31090940

RGD:407445926, RGD:407445926

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

disease_progression
severity

mRNA:increased expression:liver

RGD

PMID:26576483 PMID:26576483

RGD:14695016, RGD:14695016

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NEDD8 ubiquitin like modifier

RGD

NCBI chr15:29,153,556...29,165,575
Ensembl chr15:29,153,556...29,166,160

G

NFE2 like bZIP transcription factor 2

treatment
severity

DNA:SNP:promoter:rs35652124(human)

RGD

PMID:31906014 PMID:31340446

RGD:21201307, RGD:21201311

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

ameliorates

RGD

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

ornithine transcarbamylase

protein:increased expression:serum (rat)

RGD

NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918

G

plasminogen activator, urokinase receptor

protein:increased expression:serum

RGD

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

patatin-like phospholipase domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

peroxisome proliferator activated receptor alpha

severity

DNA:knockout::increased severity in knockouts (mouse)

RGD

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

CTD Direct Evidence: marker/mechanism

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

proteasome 26S subunit, non-ATPase 14

protein:decreased expression:liver, cytosolic proteasome complex (rat)

RGD

NCBI chr 3:46,254,338...46,347,076
Ensembl chr 3:46,254,330...46,347,076

G

retinol binding protein 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399

G

RELA proto-oncogene, NF-kB subunit

protein:increased phosphorylation:liver

RGD

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 39 member 13

protein:increased expression:liver, endoplasmic reticulum (rat)

RGD

NCBI chr 3:77,039,411...77,047,528
Ensembl chr 3:77,037,565...77,049,226

G

superoxide dismutase 1

treatment

human gene in a rat model

RGD

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

treatment

RGD

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

secreted phosphoprotein 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sequestosome 1

protein:increased expression:liver

RGD

PMID:31090940 PMID:31090940

RGD:407445926, RGD:407445926

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

thromboxane A synthase 1

mRNA,protein:increased expression:liver, Kupffer cell:

RGD

NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096

G

telomerase reverse transcriptase

mRNA,protein,activity:increased expression, increased activity:kupffer cell:

RGD

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

toll-like receptor 3

treatment

RGD

PMID:23023014 PMID:30870678

RGD:21079426, RGD:21079436

NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545

G

tumor necrosis factor

treatment

mRNA:increased expression:liver (rat)

RGD

PMID:9397994 PMID:31116255 PMID:7556590 PMID:15670576

RGD:14398736, RGD:407424600, RGD:14995472, RGD:14995456

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

ubiquitin C-terminal hydrolase L5

protein:decreased expression:liver, cytosolic proteasome complex

RGD

NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502

G

vascular endothelial growth factor A

protein:increased expression:plasma

RGD

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

alcoholic neuropathy

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

insulin-like growth factor 1

RGD

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

RGD

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor 2

RGD

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

nuclear receptor subfamily 3, group C, member 1

treatment

RGD

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

alcoholic pancreatitis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carbonic anhydrase 2

RGD

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

cholecystokinin

disease_progression

protein:decreased expression:blood plasma (human)

RGD

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

CF transmembrane conductance regulator

DNA:missense mutations: :p.L1156F, Q1352H (human)

RGD

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

parathyroid hormone-like hormone

CTD Direct Evidence: marker/mechanism

NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847

G

UDP glucuronosyltransferase 1 family, polypeptide A7C

DNA:polymorphisms: :p.N129K, p.R131K, p.W208R (human)

RGD

NCBI chr 9:88,739,577...88,808,465
Ensembl chr 9:88,713,184...88,808,465

alcoholic psychosis

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 2A

DNA:SNP:promoter:-1438G>A

RGD

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

amphetamine abuse

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

CTD Direct Evidence: marker/mechanism

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA synthetase long-chain family member 6

CTD Direct Evidence: marker/mechanism

NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757

G

adenosine A2a receptor

CTD Direct Evidence: marker/mechanism

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

adenylate kinase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458

G

AKT serine/threonine kinase 1

no_association
susceptibility

CTD Direct Evidence: marker/mechanism
DNA:SNPs:introns: (rs2494743, 2498794)
DNA:SNP:intron: (rs3730358)

CTD
RGD

PMID:15982448 PMID:31654273 PMID:15982448

RGD:407419880, RGD:407419878

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

acyloxyacyl hydrolase

CTD Direct Evidence: marker/mechanism

NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148

G

activity-regulated cytoskeleton-associated protein

disease_progression

mRNA:increased expression:brain (mouse)

RGD

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

arrestin, beta 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

astrotactin 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273

G

brain-derived neurotrophic factor

CTD Direct Evidence: marker/mechanism
protein:increased expression:frontal cortex, striatum
protein:increased expression:nucleus accumbens, ventral tegmental area
mRNA:increased expression:nucleus accumbens, dorsal striatum
protein:decreased expression:hippocampus

CTD
RGD

PMID:20736000 PMID:31693929 PMID:37904065 PMID:33961872 PMID:24407463

RGD:597015747, RGD:596938173, RGD:596936246, RGD:401976437

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

catalase

treatment

RGD

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil alpha-helical rod protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308

G

Cd4 molecule

protein:decreased expression:spleen (rat)

RGD

NCBI chr 4:157,668,878...157,695,366
Ensembl chr 4:157,668,878...157,695,191

G

CD55 molecule (Cromer blood group)

CTD Direct Evidence: marker/mechanism

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

CD8 subunit alpha

protein:increased expression:spleen (rat)

RGD

NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040

G

cadherin 13

CTD Direct Evidence: marker/mechanism

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cyclin-dependent kinase 5

protein:increased expression:ventral tegmental area, nucleus accumbens (mouse)

RGD

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

complement factor H

protein:increased expression:serum:
protein:increased expression:serum, hippocampus:

RGD

PMID:22871478 PMID:22871478

RGD:7364944, RGD:7364944

NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838

G

collagen type XXVIII alpha 1 chain

CTD Direct Evidence: marker/mechanism

NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220

G

catechol-O-methyltransferase

susceptibility

CTD Direct Evidence: marker/mechanism
DNA:SNP:cd: p.V158M (human)
DNA:SNPs,haplotypes:exon,3'utr: (rs4680, rs165599) (human)
ClinVar Annotator: match by term: methamphetamine use disorder

CTD
ClinVar
RGD

PMID:15274053 PMID:25741868 PMID:33544778 PMID:21934638 PMID:17187009 More...

RGD:401959602, RGD:401940147, RGD:401940150, RGD:401940124

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cAMP responsive element binding protein 1

treatment

protein:increases activity:ventral tegmental area, nucleus accumbens (mouse)
mRNA:decreased expression:nucleus accumbens
protein:increased expression, increased phosphorylation:nucleus accumbens, ventral tegmental area

RGD

PMID:28782589 PMID:33961872 PMID:31900897

RGD:401900303, RGD:596936246, RGD:401938636

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CUB and Sushi multiple domains 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614

G

cubilin

CTD Direct Evidence: marker/mechanism

NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231

G

cytochrome P450, family 2, subfamily d, polypeptide 4

CTD Direct Evidence: marker/mechanism

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

dendrocyte expressed seven transmembrane protein

CTD Direct Evidence: marker/mechanism

NCBI chr 7:70,807,455...70,822,067
Ensembl chr 7:70,807,581...70,822,078

G

dopamine receptor D1

CTD Direct Evidence: marker/mechanism

PMID:18363855 PMID:19444617

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

CTD Direct Evidence: marker/mechanism

PMID:18363855 PMID:18555060 PMID:19940168

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

CTD Direct Evidence: marker/mechanism

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dopamine receptor D4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

epoxide hydrolase 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

fragile histidine triad diadenosine triphosphatase

CTD Direct Evidence: marker/mechanism

NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340

G

FKBP prolyl isomerase family member 15

CTD Direct Evidence: marker/mechanism

NCBI chr 5:75,750,786...75,815,038
Ensembl chr 5:75,750,787...75,814,990

G

Fos proto-oncogene, AP-1 transcription factor subunit

CTD Direct Evidence: marker/mechanism
protein:increased expression:nucleus accumbens,striatum
mRNA:increased expression:nucleus accumbens

CTD
RGD

PMID:19689456 PMID:18834549 PMID:24183790

RGD:405255667, RGD:405100720

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

protein:increased expression:ventral tegmental area, nucleus accumbens (mouse)
associated with stress related disorder;protein:increased expression:brain (rat)

RGD

PMID:28782589 PMID:27672362 PMID:31373119

RGD:401900303, RGD:401901183, RGD:401900735

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

gamma-aminobutyric acid type B receptor subunit 1

susceptibility

DNA:SNPs, halotypes:intron (rs2076483,rs29221,rs715044) (human)

RGD

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

gamma-aminobutyric acid type A receptor subunit gamma 2

sexual_dimorphism

CTD Direct Evidence: marker/mechanism
DNA:missense mutation:exon 8:p.K289M (rs4480617) (human)

CTD
RGD

PMID:15772696 PMID:14569258

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346

G

glutamate decarboxylase 1

susceptibility

DNA:haplotype: :rs769404��rs701492(human)

RGD

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

susceptibility

DNA:SNP: :rs2236418(human)

RGD

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

glial cell derived neurotrophic factor

treatment

CTD Direct Evidence: marker/mechanism
protein:increased expression:nucleus accumbens, ventral tegmental area

CTD
RGD

PMID:17356005 PMID:37904065 PMID:23432945

RGD:596938173, RGD:405850210

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glutamate ionotropic receptor AMPA type subunit 1

methamphetamine abuse;protein:increased expression:hippocampal formation, striatum, prefrontal cortex (rat)

RGD

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

RGD

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate metabotropic receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:107,280,099...107,293,159
Ensembl chr 8:107,280,099...107,293,146

G

glutathione S-transferase mu 1

CTD Direct Evidence: marker/mechanism

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

CTD Direct Evidence: marker/mechanism

PMID:18186040 PMID:19254865

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

histone deacetylase 8

mRNA:decreased expression:striatum (rat)

RGD

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

G

heparan sulfate-glucosamine 3-sulfotransferase 4

CTD Direct Evidence: marker/mechanism

NCBI chr 1:178,539,078...178,944,850
Ensembl chr 1:178,539,093...178,944,107

G

5-hydroxytryptamine receptor 1B

CTD Direct Evidence: therapeutic

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 3A

CTD Direct Evidence: marker/mechanism

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

5-hydroxytryptamine receptor 6

CTD Direct Evidence: marker/mechanism

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

G

LARGE xylosyl- and glucuronyltransferase 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:11,603,129...12,048,930
Ensembl chr19:11,603,129...12,048,930

G

leucine rich repeat and Ig domain containing 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:50,370,744...51,687,252
Ensembl chr 5:50,367,101...50,516,956

G

mitogen activated protein kinase kinase 5

CTD Direct Evidence: marker/mechanism

NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983

G

myoglobin

RGD

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

mitochondrial amidoxime reducing component 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796

G

mitochondrial amidoxime reducing component 2

CTD Direct Evidence: marker/mechanism

NCBI chr13:96,362,810...96,397,284

G

myosin Vb

CTD Direct Evidence: marker/mechanism

NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745

G

nitric oxide synthase 1

CTD Direct Evidence: marker/mechanism

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

neuropeptide Y receptor Y1

CTD Direct Evidence: marker/mechanism
DNA:SNP:intron: (rs7687423) (human)

CTD
RGD

PMID:19566775 PMID:19566775

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

neuregulin 1

CTD Direct Evidence: marker/mechanism

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

neurotrophic receptor tyrosine kinase 2

mRNA:increased expression:nucleus accumbens
protein:increased expression:frontal cortex, striatum
protein:altered expression:nucleus accumbens, ventral tegmental area

RGD

PMID:33961872 PMID:31693929 PMID:37904065 PMID:34273388

RGD:596936246, RGD:597015747, RGD:596938173, RGD:596938171

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

opioid receptor, mu 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

procollagen C-endopeptidase enhancer 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:96,193,461...96,251,116
Ensembl chr 8:96,193,461...96,251,114

G

phosphodiesterase 4B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

phosphodiesterase 4D

CTD Direct Evidence: marker/mechanism

NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884

G

phosphodiesterase 6C

CTD Direct Evidence: marker/mechanism

NCBI chr 1:235,909,583...235,965,435
Ensembl chr 1:235,909,775...235,965,315

G

prodynorphin

CTD Direct Evidence: marker/mechanism
mRNA:increased expression:nucleus acccumbens
mRNA:increased expression:nucleus accumbens
mRNA:increased expression:central amygdaloid nucleus
mRNA:altered expression:brain
DNA:repeat:promoter:rs35286251 (human)

CTD
RGD

PMID:16529859 PMID:27989838 PMID:22390687 PMID:12523490 PMID:16289352 More...

RGD:401851910, RGD:401851043, RGD:401850585, RGD:401850564, RGD:401850552

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

protein interacting with PRKCA 1

CTD Direct Evidence: marker/mechanism

NCBI chr 7:110,796,623...110,816,850
Ensembl chr 7:110,797,117...110,816,848

G

plasminogen activator, tissue type

CTD Direct Evidence: marker/mechanism

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

POU class 5 homeobox 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

PR/SET domain 2

CTD Direct Evidence: marker/mechanism

NCBI chr 5:155,421,066...155,531,884
Ensembl chr 5:155,422,134...155,531,825

G

protein kinase cAMP-activated catalytic subunit alpha

treatment

protein:increased expression, increased phosphorylation:nucleus accumbens, ventral tegmental area

RGD

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase cGMP-dependent 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080

G

prokineticin receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718

G

pleckstrin and Sec7 domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547

G

RALY heterogeneous nuclear ribonucleoprotein

CTD Direct Evidence: marker/mechanism

NCBI chr 3:143,306,039...143,370,542
Ensembl chr 3:143,306,300...143,370,539

G

Rap guanine nucleotide exchange factor 5

CTD Direct Evidence: marker/mechanism

NCBI chr 6:138,445,184...138,679,943
Ensembl chr 6:138,437,991...138,679,936

G

RELA proto-oncogene, NF-kB subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulator of G-protein signaling 17

CTD Direct Evidence: marker/mechanism

NCBI chr 1:42,222,248...42,324,625
Ensembl chr 1:42,227,070...42,324,609

G

serpin family A member 5

CTD Direct Evidence: marker/mechanism

NCBI chr 6:123,009,224...123,028,412
Ensembl chr 6:123,023,306...123,028,407

G

sarcoglycan zeta

CTD Direct Evidence: marker/mechanism

NCBI chr16:53,660,283...54,740,811
Ensembl chr16:53,660,502...54,735,193

G

SH3 domain containing ring finger 3

CTD Direct Evidence: marker/mechanism

NCBI chr20:26,765,278...27,099,261
Ensembl chr20:26,765,015...27,099,257

G

solute carrier family 6 member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

solute carrier family 6 member 9

CTD Direct Evidence: marker/mechanism

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

SET and MYND domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253

G

synuclein alpha

treatment

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:15542733 PMID:32278788 PMID:20551914

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

transient receptor potential cation channel, subfamily M, member 3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:219,673,200...220,557,610
Ensembl chr 1:219,672,892...220,560,717

G

ubiquitin specific peptidase 48

CTD Direct Evidence: marker/mechanism

NCBI chr 5:149,800,189...149,867,838
Ensembl chr 5:149,800,179...149,867,719

G

zinc finger protein 385D

CTD Direct Evidence: marker/mechanism

NCBI chr15:5,040,182...5,849,975
Ensembl chr15:5,042,572...5,423,367

G

zinc finger protein 423

CTD Direct Evidence: marker/mechanism

NCBI chr19:19,111,213...19,407,373
Ensembl chr19:19,110,238...19,407,373

Anthracycline-induced Cardiotoxicity

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

susceptibility

DNA:missense mutation:cds:p.G671V (human)

RGD

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

activin A receptor type 2B

treatment

human construct in mouse model

RGD

NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458

G

calpain 2

treatment

RGD

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

ERCC excision repair 2, TFIIH core complex helicase subunit

associated with Leukemia, Myeloid, Acute;DNA:SNP:exon:p.K751Q (rs13181) (human)

RGD

NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102

antidepressant type abuse

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

basic helix-loop-helix ARNT like 1

mRNA:increased expression:hippocampal formation (mouse)

RGD

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

clock circadian regulator

mRNA:increased expression:hippocampal formation (mouse)

RGD

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

cryptochrome circadian regulator 1

mRNA:increased expression:hippocampal formation (mouse)

RGD

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

period circadian regulator 1

mRNA:decreased expression: hippocampal formation, caudate-putamen (mouse)

RGD

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

mRNA:increased expression, decreased expression:hippocampal formation, caudate-putamen (mouse)

RGD

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

Arsenic Poisoning

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

A-kinase anchoring protein 9

CTD Direct Evidence: marker/mechanism

NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606

G

aminolevulinate dehydratase

protein:decreased activity:blood (rat)

RGD

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

aquaporin 9

CTD Direct Evidence: marker/mechanism

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

arsenite methyltransferase

CTD Direct Evidence: marker/mechanism|therapeutic

PMID:21447609 PMID:26366667 PMID:35226250

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

ataxin 7

CTD Direct Evidence: marker/mechanism

NCBI chr15:11,117,360...11,262,818
Ensembl chr15:11,118,886...11,263,106

G

C-C motif chemokine ligand 20

CTD Direct Evidence: marker/mechanism

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 4

CTD Direct Evidence: marker/mechanism

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine receptor like 2

CTD Direct Evidence: marker/mechanism

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664

G

CD44 molecule

CTD Direct Evidence: marker/mechanism

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD83 molecule

CTD Direct Evidence: marker/mechanism

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

cyclin-dependent kinase inhibitor 1A

protein:increased expression:skin:

RGD

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

C-reactive protein

CTD Direct Evidence: marker/mechanism

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X-C motif chemokine ligand 2

CTD Direct Evidence: marker/mechanism

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

ERCC excision repair 1, endonuclease non-catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 3, TFIIH core complex helicase subunit

CTD Direct Evidence: marker/mechanism

NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329

G

ERCC excision repair 4, endonuclease catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
Ensembl chr10:2,419,038...2,448,369

G

growth arrest and DNA-damage-inducible, beta

CTD Direct Evidence: marker/mechanism

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

golgin A4

CTD Direct Evidence: marker/mechanism

NCBI chr 8:118,208,200...118,285,003

G

glutathione-disulfide reductase

RGD

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

heat shock protein family A (Hsp70) member 1B

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

inhibitor of DNA binding 2

CTD Direct Evidence: marker/mechanism

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

immediate early response 3

CTD Direct Evidence: marker/mechanism

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

insulin-like growth factor 2 mRNA binding protein 2

CTD Direct Evidence: marker/mechanism

NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377

G

interleukin 1 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

CTD Direct Evidence: marker/mechanism

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

CTD Direct Evidence: marker/mechanism

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

inositol polyphosphate-5-phosphatase A

CTD Direct Evidence: marker/mechanism

NCBI chr 1:194,190,086...194,380,429
Ensembl chr 1:194,190,393...194,380,428

G

potassium inwardly-rectifying channel, subfamily J, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445

G

keratin 10

CTD Direct Evidence: marker/mechanism

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

CTD Direct Evidence: marker/mechanism

NCBI chr 2:211,530,598...211,546,845
Ensembl chr 2:211,530,602...211,546,821

G

multiple inositol-polyphosphate phosphatase 1

CTD Direct Evidence: marker/mechanism

NCBI chr 1:230,354,483...230,379,730
Ensembl chr 1:230,354,438...230,379,730

G

microRNA 145

CTD Direct Evidence: marker/mechanism

NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727

G

microRNA 155

miRNA:increased expression:serum

RGD

NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718

G

metallothionein 1

CTD Direct Evidence: marker/mechanism

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

methylenetetrahydrofolate reductase

CTD Direct Evidence: marker/mechanism

NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797

G

NEDD4 binding protein 2-like 2

CTD Direct Evidence: marker/mechanism

NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784

G

NADH:ubiquinone oxidoreductase subunit B8

CTD Direct Evidence: marker/mechanism

NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817

G

NLR family, pyrin domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nuclear receptor subfamily 4, group A, member 2

CTD Direct Evidence: marker/mechanism

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

phosphodiesterase 4B

CTD Direct Evidence: marker/mechanism

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

pellino E3 ubiquitin protein ligase 1

CTD Direct Evidence: marker/mechanism

NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285
Ensembl chr 1:95,254,589...95,308,285

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

CTD Direct Evidence: marker/mechanism

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

protein inhibitor of activated STAT, 1

CTD Direct Evidence: marker/mechanism

NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905

G

purine nucleoside phosphorylase

CTD Direct Evidence: marker/mechanism

NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986

G

pentraxin 3

CTD Direct Evidence: marker/mechanism

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

regulatory factor X3

CTD Direct Evidence: marker/mechanism

NCBI chr 1:225,449,872...225,709,622
Ensembl chr 1:225,456,187...225,709,402

G

regulator of G-protein signaling 1

CTD Direct Evidence: marker/mechanism

NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984

G

ring finger protein 20

protein:increased expression:urine (human)

RGD

NCBI chr 5:63,976,063...64,001,754
Ensembl chr 5:63,976,045...64,001,754

G

RUN and FYVE domain containing 3

CTD Direct Evidence: marker/mechanism

NCBI chr14:19,431,530...19,506,476
Ensembl chr14:19,432,524...19,507,004

G

splicing factor proline and glutamine rich

CTD Direct Evidence: marker/mechanism

NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472

G

SKI-like proto-oncogene

CTD Direct Evidence: marker/mechanism

NCBI chr 2:112,247,047...112,275,176
Ensembl chr 2:112,247,051...112,275,080

G

superoxide dismutase 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 18

CTD Direct Evidence: marker/mechanism

NCBI chr 3:168,785,488...168,787,290
Ensembl chr 3:168,785,490...168,787,290

G

signal recognition particle 68

CTD Direct Evidence: marker/mechanism

NCBI chr10:101,481,213...101,508,035
Ensembl chr10:101,481,212...101,508,035

G

single stranded DNA binding protein 1

CTD Direct Evidence: marker/mechanism

NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135

G

TATA-box binding protein associated factor, RNA polymerase I subunit D

CTD Direct Evidence: marker/mechanism

NCBI chr 8:12,146,511...12,156,647
Ensembl chr 8:12,146,605...12,156,618

G

tumor necrosis factor

CTD Direct Evidence: marker/mechanism

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

CTD Direct Evidence: marker/mechanism

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TRAF2 and NCK interacting kinase

CTD Direct Evidence: marker/mechanism

NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750

G

tumor protein p53

CTD Direct Evidence: marker/mechanism

PMID:18621066 PMID:19203779

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

transformer 2 alpha

CTD Direct Evidence: marker/mechanism

NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712

G

trafficking protein particle complex subunit 10

CTD Direct Evidence: marker/mechanism

NCBI chr20:10,438,737...10,499,074
Ensembl chr20:10,438,737...10,499,074

G

ubiquitin-conjugating enzyme E2E 1

CTD Direct Evidence: marker/mechanism

NCBI chr15:7,439,751...7,493,410
Ensembl chr15:7,439,759...7,493,400

G

USO1 vesicle transport factor

CTD Direct Evidence: marker/mechanism

NCBI chr14:15,866,638...15,932,185
Ensembl chr14:15,866,638...15,932,171

G

ubiquitin specific peptidase 13

CTD Direct Evidence: marker/mechanism

NCBI chr 2:115,576,912...115,689,153
Ensembl chr 2:115,577,091...115,686,222

G

zinc finger AN1-type containing 6

CTD Direct Evidence: marker/mechanism

NCBI chr 1:138,581,002...138,652,052
Ensembl chr 1:138,581,002...138,651,939

G

zinc finger protein 267

CTD Direct Evidence: marker/mechanism

NCBI chr 2:119,017,280...119,035,885
Ensembl chr 2:119,017,285...119,031,900

aspirin-induced respiratory disease

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcium voltage-gated channel auxiliary subunit gamma 6

susceptibility

DNA:SNP,haplotype:rs192808(human)

RGD

NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341

G

C-C motif chemokine receptor 3

CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:20485159 PMID:20022477

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

cysteinyl leukotriene receptor 1

CTD Direct Evidence: marker/mechanism

PMID:16502481 PMID:17641958 PMID:20485159

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

cysteinyl leukotriene receptor 2

DNA:SNPs: :-819T>G, 2078C>T, 2534A>G (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15970796

NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136

G

FA complementation group C

DNA:haplotype::rs4647416(human)

RGD

NCBI chr17:1,680,660...1,822,610
Ensembl chr17:1,681,324...1,829,376

G

interleukin 4

susceptibility

DNA:SNPs:promoter,5'UTR,intron:multiple

RGD

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

leukotriene C4 synthase

CTD Direct Evidence: marker/mechanism

PMID:9393345 PMID:9466979 PMID:10970818 PMID:20485159

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

membrane spanning 4-domains A2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:208,440,179...208,448,716
Ensembl chr 1:208,440,361...208,448,310

G

periostin

CTD Direct Evidence: marker/mechanism

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

G

prostaglandin D2 receptor 2

CTD Direct Evidence: marker/mechanism

NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213

G

prostaglandin E receptor 2

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15496426 PMID:16502481

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin I2 receptor

CTD Direct Evidence: marker/mechanism

NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979

G

prostaglandin-endoperoxide synthase 2

protein:increased expression:mast cell
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:9487340

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RT1 class II, locus Ba

susceptibility

RGD

NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744

G

RT1 class II, locus Bb

susceptibility

RGD

NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597

G

RT1 class II, locus Db1

susceptibility

RGD

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

RT1 class II, locus Hb, pseudogene 1

CTD Direct Evidence: marker/mechanism

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

transporter 2, ATP binding cassette subfamily B member

RGD

NCBI chr20:4,636,347...4,650,387
Ensembl chr20:4,636,357...4,650,407

G

T-box transcription factor 21

ClinVar Annotator: match by term: Asthma, aspirin-induced, susceptibility to
CTD Direct Evidence: marker/mechanism

PMID:15806396 PMID:16502481

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

thromboxane A2 receptor

susceptibility

DNA:polymorphism: :795T>C (human)
CTD Direct Evidence: marker/mechanism

CTD
RGD

PMID:16502481 PMID:20485159 PMID:15898979

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

asthma, nasal polyps, and aspirin intolerance

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 15-lipoxygenase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

PMID:17959182 PMID:21558275 PMID:25741868 PMID:30643255

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

leukotriene C4 synthase

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

prostaglandin E receptor 2

susceptibility

CTD Direct Evidence: marker/mechanism

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

T-box transcription factor 21

susceptibility

ClinVar Annotator: match by term: Asthma, nasal polyps, and aspirin intolerance
CTD Direct Evidence: marker/mechanism

ClinVar
OMIM
CTD

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

Binge Drinking

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

mRNA:altered exxpression:liver (rat)

RGD

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

mRNA:altered exxpression:liver (rat)

RGD

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

brain-derived neurotrophic factor

protein:altered expression:amygdala, pyriform cortex, bed nucleus of stria terminalis

RGD

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

carbonic anhydrase 3

associated with Alcoholic Liver Diseases;protein:decreased expression:liver

RGD

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

corticotropin releasing hormone receptor 1

mRNA:decreased expression:adenohypophysis

RGD

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

cytochrome P450, family 2, subfamily e, polypeptide 1

associated with Alcoholic Liver Diseases;protein:increased expression:liver
mRNA:altered exxpression:liver (rat)
protein:increased expression, increased nitration

RGD

PMID:25236742 PMID:22545783 PMID:23413777 PMID:29404485 PMID:25236742

RGD:14700891, RGD:7495839, RGD:405100715, RGD:14700911, RGD:14700891

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

DNA methyltransferase 1

protein:increased expression:nucleus accumbens:

RGD

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

dopamine receptor D1

associated with human immunodeficiency virus infectious disease;mRNA:altered expression:liver,spleen (rat)

RGD

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

mRNA:altered exxpression:spleen (rat)

RGD

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

associated with human immunodeficiency virus infectious disease;mRNA:altered expression:liver,spleen (rat)

RGD

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dopamine receptor D4

susceptibility

DNA:repeats:exon:
mRNA:altered exxpression:spleen (rat)

RGD

PMID:19393859 PMID:23413777

RGD:401960068, RGD:405100715

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

EF-hand domain family, member D2